Humacyte (HUMA): Director received 80K units

80K

Derivative units

Traded

Jun 11, 2026

Filed

Jun 12, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Apr 21, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors
2. May 4, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On May 4, 2026, Humacyte, Inc. (the “Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification that, for the 30 consecutive business days ended May 1, 2026, the bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”), had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Global…”
3. May 18, 2026Insider · 3 peopleInsiders: 1 purchase (~$10K), 2 sales (~$82K)
4. May 19, 2026Insider · Bought outside the usual windowDirector purchased ~$50K of HUMA shares in the open market
5. Jun 9, 2026Company filing · Form 8-K · Bylaws or charter, Shareholder voteChanged its bylaws, charter or fiscal year, and held a shareholder vote
6. Jun 10, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors

What came next

1. Jul 31, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On July 31, 2026, Humacyte, Inc. (the “Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification that, for the 30 consecutive business days ended July 30, 2026, the bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”), had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq…”
2. Aug 12, 2026Company filing · Form 8-K · ResultsReported its results
3. Aug 17, 2026Insider · Their first buy on recordDirector purchased ~$18K of HUMA shares in the open market
4. Aug 20, 2026InsiderDirector purchased ~$6.9K of HUMA shares in the open market
5. Sep 14, 2026Insider · 8 days before an 8-KDirector purchased ~$5.6K of HUMA shares in the open market
6. Sep 22, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On September 22, 2026, the Board of Directors (the “Board”) of Humacyte, Inc. (the “Company”), appointed Scott Coward and Paul Kuznik to the Board. Mr. Coward will serve as a Class I director with a term expiring in 2028, or until his earlier death, resignation, retirement, disqualification or removal.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Humacyte

For Humacyte, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its HUMA page.

Other recent filings by Keith Anthony Jones, Director

• SEC Form 4 at Humacyte (HUMA)Sep 15, 2026
• SEC Form 4 at Humacyte (HUMA)Aug 21, 2026
• SEC Form 4 at Humacyte (HUMA)Aug 19, 2026

The full history of Keith Anthony Jones, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Humacyte

• SEC Form 4Sep 15, 2026
• SEC Form 4Aug 21, 2026
• SEC Form 4Aug 19, 2026
• SEC Form 4May 20, 2026
• SEC Form 4May 20, 2026
• SEC Form 4May 20, 2026

Everything OQRO holds on this company is on its HUMA page.